Synapse - Jae Park

Search Within

Jae Hong Park

Results (68)

Impact of bridging chemotherapy on clinical outcomes of CD19-specific CAR T cell therapy in children/young adults with relapsed/refractory B cell acute lymphoblastic leukemia

Journal Article

Shahid, S.; Ramaswamy, K.; Flynn, J.; Mauguen, A.; Perica, K.; Park, J. H.; Forlenza, C. J.; Shukla, N. N.; Steinherz, P. G.; Margossian, S. P.; more...
Transplantation and Cellular Therapy (2022)

Fulltext@MSK | Save

Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma

Meeting Abstract

Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
Blood (2021)

Fulltext@MSK | Save

Incorporation of bacterial immunoevasins to protect cell therapies from host antibody-mediated immune rejection

Journal Article

Peraro, L.; Bourne, C. M.; Dacek, M. M.; Akalin, E.; Park, J. H.; Smith, E. L.; Scheinberg, D. A.
Molecular Therapy (2021)

Fulltext@MSK | Save

Bridging chemotherapy prior to CD19-specific CAR T-cell therapy in children/young adults with relapsed/refractory acute lymphoblastic leukemia

Meeting Abstract

Shahid, S.; Ramaswamy, K.; Flynn, J.; Mauguen, A.; Boelens, J. J.; Forlenza, C.; Kernan, N.; Shukla, N.; Steinherz, P.; Sulis, M. L.; more...
Pediatric Blood and Cancer (2021)

Fulltext@MSK | Save

Decreased neuroprotective analytes on day of infusion of chimeric antigen receptor (CAR) T cells are associated with neurotoxicity

Meeting Abstract

Lakkaraja, M.; Hosszu, K.; McAvoy, D.; Mauguen, A.; Purdon, T. J.; Khakoo, Y.; Santomasso, B. D.; Riviere, I.; Sadelain, M.; Curran, K. J.; more...
Bone Marrow Transplantation (2021)

Fulltext@MSK | Save

ADCLEC.syn1 is a novel combinatorial CAR platform for enhanced therapeutic index in AML

Meeting Abstract

Haubner, S.; Mansilla-Soto, J.; Nataraj, S.; Park, J.; Wang, X.; Rivière, I.; Sadelain, M.
Molecular Therapy (2021)

Fulltext@MSK | Save

Predictors for neurotoxicity on day of infusion of chimeric antigen receptor (CAR) T cells using discovery proteomics platform

Meeting Abstract

Lakkaraja, M.; Hosszu, K.; McAvoy, D.; Mauguen, A.; Purdon, T. J.; Auchincloss, T.; Klein, E.; Khakoo, Y.; Santomasso, B.; Senechal, B.; more...
Cytotherapy (2021)

Fulltext@MSK | Save

A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory B-cell malignancies

Meeting Abstract

Park, J. H.; Riviere, I.; Sikder, D. S.; Bermudez, V. P.; Senechal, B.; Wang, X.; Auchincloss, T. H.; Diamonte, C.; Halton, E.; Palomba, M. L.; more...
Blood (2020)

Fulltext@MSK | Save

Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: Final results of a phase I clinical trial

Meeting Abstract

Mailankody, S.; Ghosh, A.; Staehr, M.; Purdon, T. J.; Roshal, M.; Halton, E.; Diamonte, C.; Pineda, J.; Anant, P.; Bernal, Y.; more...
Blood (2018)

Fulltext@MSK | Save

Ruxolitinib in combination with dasatinib and dexamethasone is an active and well-tolerated chemotherapy-sparing oral induction regimen for adults with Philadelphia chromosome-positive ALL: Results of a phase I trial

Meeting Abstract

Geyer, M. B.; Burke, P. W.; King, A. C.; Mauro, M. J.; Tallman, M. S.; Levine, R. L.; Sherr, C. J.; Douer, D.; Park, J. H.
Blood (2018)

Fulltext@MSK | Save